You are here: Industry Insights > HIV regimen

News List

Can new Dovato data jump-start uptake of 2-drug HIV regimen? ViiV hopes so fiercepharma
July 28, 2019
Previous clinical results for ViiV Healthcare’s vaunted two-drug HIV regimens have yet to pose a big threat to chief rival Gilead Sciences. But the GlaxoSmithKline joint venture aims to change that with two new sets of data.
ViiV reaches another milestone in the development of a long-acting HIV regimen pharmaceutical-technology
July 31, 2017
On July 24, 2017, ViiV Healthcare announced positive results from 96-week data obtained from a Phase IIb, open-label study (LATTE-2) investigating the safety and efficacy of a two-drug...
ViiV study shows efficacy of two-drug HIV regimen pharmatimes
February 16, 2017
ViiV Healthcare has unveiled late-stage data showing that an experimental two-drug regimen of its dolutegravir and Janssen Science's rilpivirine was comparable in efficacy to three- or four-drug antiretroviral regimens in virologically suppressed patients